ES3070919T3 - Crystalline forms of a glp-1 receptor agonist and preparation methods therefor - Google Patents
Crystalline forms of a glp-1 receptor agonist and preparation methods thereforInfo
- Publication number
- ES3070919T3 ES3070919T3 ES22910190T ES22910190T ES3070919T3 ES 3070919 T3 ES3070919 T3 ES 3070919T3 ES 22910190 T ES22910190 T ES 22910190T ES 22910190 T ES22910190 T ES 22910190T ES 3070919 T3 ES3070919 T3 ES 3070919T3
- Authority
- ES
- Spain
- Prior art keywords
- compound
- crystalline form
- methyl
- chloro
- fluorophenyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Diabetes (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111586541 | 2021-12-23 | ||
| PCT/CN2022/141407 WO2023116879A1 (zh) | 2021-12-23 | 2022-12-23 | 一种glp-1受体激动剂的结晶形式及其制备方法 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES3070919T3 true ES3070919T3 (en) | 2026-06-18 |
Family
ID=86901327
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES22910190T Active ES3070919T3 (en) | 2021-12-23 | 2022-12-23 | Crystalline forms of a glp-1 receptor agonist and preparation methods therefor |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20250049778A1 (cg-RX-API-DMAC7.html) |
| EP (2) | EP4455140B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2024547112A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20240125004A (cg-RX-API-DMAC7.html) |
| CN (1) | CN118401518A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2022422997A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3241677A1 (cg-RX-API-DMAC7.html) |
| DK (1) | DK4455140T3 (cg-RX-API-DMAC7.html) |
| ES (1) | ES3070919T3 (cg-RX-API-DMAC7.html) |
| FI (1) | FI4455140T3 (cg-RX-API-DMAC7.html) |
| MX (1) | MX2024007907A (cg-RX-API-DMAC7.html) |
| PL (1) | PL4455140T3 (cg-RX-API-DMAC7.html) |
| PT (1) | PT4455140T (cg-RX-API-DMAC7.html) |
| TW (1) | TW202328115A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2023116879A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4777197A2 (en) | 2023-09-14 | 2026-07-22 | Ascletis Pharma (China) Co., Limited | Glp-1r agonist and therapeutic method thereof |
| WO2025109387A1 (en) | 2023-11-24 | 2025-05-30 | Ascletis Pharma (China) Co., Limited | Glp-1r agonist and therapeutic method thereof |
| TW202600132A (zh) | 2024-03-08 | 2026-01-01 | 美商安尼波那生物公司 | 用於治療肥胖症及提高減重之方法 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3045644C (en) * | 2018-06-13 | 2024-01-16 | Pfizer Inc. | Glp-1 receptor agonists and uses thereof |
| EP4130005A4 (en) * | 2020-04-01 | 2024-04-24 | Hangzhou Zhongmeihuadong Pharmaceutical Co., Ltd. | CRYSTALLINE FORM A OF A GLP-1 RECEPTOR AGONIST AND METHOD OF MANUFACTURING THEREOF |
| PT4157832T (pt) * | 2020-05-27 | 2024-07-30 | Qilu Regor Therapeutics Inc | Formas de sal e cristal de agonistas de glp-1r e utilizações dos mesmos |
| JP7812052B2 (ja) * | 2020-09-01 | 2026-02-09 | 江蘇恒瑞医薬股▲ふん▼有限公司 | 縮合イミダゾール誘導体、その調製方法及びその医薬的応用 |
| CN117177970A (zh) * | 2021-04-30 | 2023-12-05 | 上海翰森生物医药科技有限公司 | 多环类衍生物调节剂、其制备方法和应用 |
-
2022
- 2022-12-23 KR KR1020247024148A patent/KR20240125004A/ko active Pending
- 2022-12-23 PT PT229101902T patent/PT4455140T/pt unknown
- 2022-12-23 US US18/722,345 patent/US20250049778A1/en active Pending
- 2022-12-23 MX MX2024007907A patent/MX2024007907A/es unknown
- 2022-12-23 WO PCT/CN2022/141407 patent/WO2023116879A1/zh not_active Ceased
- 2022-12-23 EP EP22910190.2A patent/EP4455140B1/en active Active
- 2022-12-23 AU AU2022422997A patent/AU2022422997A1/en active Pending
- 2022-12-23 ES ES22910190T patent/ES3070919T3/es active Active
- 2022-12-23 DK DK22910190.2T patent/DK4455140T3/da active
- 2022-12-23 EP EP26159633.2A patent/EP4725484A3/en active Pending
- 2022-12-23 FI FIEP22910190.2T patent/FI4455140T3/fi active
- 2022-12-23 TW TW111149828A patent/TW202328115A/zh unknown
- 2022-12-23 PL PL22910190.2T patent/PL4455140T3/pl unknown
- 2022-12-23 CN CN202280084770.1A patent/CN118401518A/zh active Pending
- 2022-12-23 CA CA3241677A patent/CA3241677A1/en active Pending
- 2022-12-23 JP JP2024537982A patent/JP2024547112A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| PT4455140T (pt) | 2026-05-22 |
| CA3241677A1 (en) | 2023-06-29 |
| DK4455140T3 (da) | 2026-05-26 |
| EP4455140A4 (en) | 2025-04-09 |
| PL4455140T3 (pl) | 2026-06-29 |
| EP4455140A1 (en) | 2024-10-30 |
| FI4455140T3 (fi) | 2026-05-28 |
| US20250049778A1 (en) | 2025-02-13 |
| EP4725484A2 (en) | 2026-04-15 |
| AU2022422997A1 (en) | 2024-07-11 |
| MX2024007907A (es) | 2024-07-12 |
| CN118401518A (zh) | 2024-07-26 |
| JP2024547112A (ja) | 2024-12-26 |
| TW202328115A (zh) | 2023-07-16 |
| EP4455140B1 (en) | 2026-04-01 |
| KR20240125004A (ko) | 2024-08-19 |
| WO2023116879A1 (zh) | 2023-06-29 |
| EP4725484A3 (en) | 2026-06-10 |